mRNA-1944 encodes a fully human IgG antibody originally isolated from B cells of a patient with a prior history of potent immunity against Chikungunya infection.
It is composed of two mRNAs that encode the heavy and light chains of this anti-Chikungunya antibody within Moderna’s proprietary lipid nanoparticle (LNP) technology.
mRNA-1944 is a developmental vaccine candidate to prevent diseases caused by the Chikungunya virus.
January 2019, Moderna announced the initiation of a limited, Phase 1 study of mRNA-1944 against the chikungunya virus.
Clinical Trial NCT03829384: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
This phase 1 clinical trial is a single-center, randomized, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of a single dose of mRNA 1944 in healthy adult subjects.
Cohorts of mRNA-1944 are planned to be investigated in a sequential dose escalation manner.